You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

ADAR1 293T Transfected Lysate - (positive control) (ab94050)

Submit a Question

Overview

  • Product nameADAR1 293T Transfected Lysate - (positive control)
  • General notesab94050 is a 293T cell transfected lysate in which Human ADAR1 has been transiently over-expressed using a pCMV-ADAR1 plasmid. The lysate is provided in 1X Sample Buffer. Note: For more detailes about how the transfected lysate was prepared view preparation notes
  • Tested applicationsWB more details

Properties

  • BackgroundFunction: Converts multiple adenosines to inosines and creates I/U mismatched base pairs in double-helical RNA substrates without apparent sequence specificity. Has been found to modify more frequently adenosines in AU-rich regions, probably due to the relative ease of melting A/U base pairs as compared to G/C pairs. Functions to modify viral RNA genomes and may be responsible for hypermutation of certain negative-stranded viruses. Edits the messenger RNAs for glutamate receptor (GLUR) subunits by site-selective adenosine deamination. Produces low-level editing at the GLUR-B Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Binds to short interfering RNAs (siRNA) without editing them and suppresses siRNA-mediated RNA interference. Binds to ILF3/NF90 and up-regulates ILF3-mediated gene expression. Tissue specificity: Ubiquitously expressed, highest levels were found in brain and lung. Disease: Defects in ADAR are a cause of dyschromatosis symmetrical hereditaria (DSH) [MIM:127400]; also known as reticulate acropigmentation of Dohi. DSH is a pigmentary genodermatosis of autosomal dominant inheritance characterized by a mixture of hyperpigmented and hypopigmented macules distributed on the dorsal parts of the hands and feet. Similarity: Contains 1 A to I editase domain. Contains 2 DRADA repeats. Contains 3 DRBM (double-stranded RNA-binding) domains. PTM: Sumoylation reduces RNA-editing activity.

    • Applications

    Our Abpromise guarantee covers the use of ab94050 in the following tested applications.

    The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

    Application Notes
    WB
  • Application notesWB: Use at an assay dependent dilution.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.

    • ADAR1 293T Transfected Lysate - (positive control) images

    • SDS-PAGE - ADAR1 293T Transfected Lysate - (positive control) (ab94050)
      SDS-PAGE - ADAR1 293T Transfected Lysate - (positive control) (ab94050)
      ab94050 at 15µg/lane on an SDS-PAGE gel.
    • Western blot - ADAR1 293T Transfected Lysate - (positive control) (ab94050)
      Western blot - ADAR1 293T Transfected Lysate - (positive control) (ab94050)
      All lanes : Anti-ADAR1 antibody (ab88574) at 1/500 dilution

      Lane 1 : ADAR1 293T Transfected Lysate - (positive control) (ab94050)
      Lane 2 : 293T non-transfected lysate

      Lysates/proteins at 25 µg per lane.

      Secondary
      Goat Anti-mouse IgG (H and L) HRP conjugated at 1/2500 dilution

    References for ADAR1 293T Transfected Lysate - (positive control) (ab94050)

    ab94050 has not yet been referenced specifically in any publications.

    Publishing research using ab94050 ? Please let us know so that we can cite the reference in this datasheet

    Product Wall

    Submit a Question for ab94050

    There are currently no Questions for ab94050.
    Please use the link above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"